<DOC>
	<DOC>NCT01453946</DOC>
	<brief_summary>A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.</brief_summary>
	<brief_title>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</brief_title>
	<detailed_description>A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit. All subjects must weight &gt;= 15 kg at the time of enrollment. Subjects must have been diagnosed and treated for active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology and have a PCDAI &lt;= 10 Subjects who have had any previous intestinal resection proximal to and including the ascending colon. Subjects with evidence of active Crohn's disease (PCDAI &gt; 10) and/or stricturing, prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications. Subjects with morning cortisol level &lt;150 nmol/l (5.4 ug/dl) or DHEAS below normal range for age and gender (NOTE: Subjects from the induction protocol with abnormal morning cortisol/DHEAS levels at Visit 4, who otherwise meet the eligibility criteria, may be enrolled if the investigator decides that Entocort 6 mg is an appropriate therapy option.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>